VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

rMVA-GnGc (Rift Valley fever virus)
Vaccine Information
  • Vaccine Name: rMVA-GnGc (Rift Valley fever virus)
  • Target Pathogen: Rift Valley Fever virus
  • Target Disease: Rift valley fever
  • Vaccine Ontology ID: VO_0004663
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Host Species as Laboratory Animal Model: lambs
  • Vector: Modified Vaccinia Ankara (MVA) virus vaccine vector
  • Preparation: A modified vaccinia virus Ankara (MVA) vectored vaccine encoding the Rift Valley Fever virus (RVFV) glycoproteins Gn and Gc in lambs (Busquets et al., 2014).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Sheep Response

  • Vaccination Protocol: Three groups of six to seven lambs were immunized as follows: one group received the vaccine (termed rMVA-GnGc), a second group received an MVA vector (vector control) and a third group received saline solution (non-vaccinated control) (Busquets et al., 2014).
  • Vaccine Immune Response Type: VO_0000287
  • Challenge Protocol: Fourteen days post vaccination, all animals were subcutaneously challenged with 105 TCID50 of the virulent RVFV isolate 56/74 and vaccine efficacy assessed using standard endpoints (Busquets et al., 2014).
  • Efficacy: The data suggests that a single dose of the rMVA-GnGc vaccine may be sufficient to reduce RVFV shedding and duration of viremia but does not provide sterile immunity nor protection from disease. Further optimization of this vaccine approach in lambs is warranted (Busquets et al., 2014).
References
Busquets et al., 2014: Busquets N, Lorenzo G, López-Gil E, Rivas R, Solanes D, Galindo-Cardiel I, Xavier Abad F, Rodríguez F, Bensaid A, Warimwe G, Gilbert SC, Domingo M, Brun A. Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs. Antiviral research. 2014; ; . [PubMed: 24933081].